If you have a UnitedHealthcare plan and your gastroenterologist has prescribed Skyrizi for Crohn's disease, the practical answer is usually yes, UnitedHealthcare can cover Skyrizi, but coverage is not automatic. The medication sits behind prior authorization and, in many plans, step therapy. Skyrizi, known generically as risankizumab-rzaa, is an interleukin-23 inhibitor that the FDA approved for moderately to severely active Crohn's disease in adults on June 17, 2022. Because it carries a high price and treats a chronic condition, UnitedHealthcare and its pharmacy benefit manager, OptumRx, apply review criteria before paying. Understanding those criteria ahead of time is the difference between a smooth approval and a frustrating delay.
How Skyrizi Works and Why Coverage Is Split
Skyrizi treats Crohn's disease with a two-part regimen, which matters for how UnitedHealthcare processes coverage. According to the FDA prescribing information, the induction phase uses 600 mg by intravenous infusion at weeks 0, 4, and 8, followed by a maintenance dose of 180 mg or 360 mg by subcutaneous injection at week 12 and every 8 weeks after that. The intravenous induction doses are typically billed under your medical benefit, while the self-injected maintenance doses run through the pharmacy benefit managed by OptumRx. UnitedHealthcare's own pharmacy coverage policy for Skyrizi confirms it applies to the subcutaneous formulations and that the intravenous loading dose is handled under a separate medical benefit prior authorization. Knowing which benefit a given dose falls under helps you anticipate two reviews rather than one.
What UnitedHealthcare Typically Requires for Approval
UnitedHealthcare generally requires prior authorization before it will pay for Skyrizi, and its published criteria spell out what a Crohn's request must show. The insurer's Skyrizi clinical pharmacy program lists, for Crohn's disease, a documented diagnosis of moderately to severely active disease, evidence that the intravenous loading dose was already approved or that the patient is established on therapy, confirmation that Skyrizi is not combined with another targeted immunomodulator, and a prescription written by or in consultation with a gastroenterologist. Many plans also layer on step therapy, which often means documenting failure of conventional treatment and frequently a preferred anti-tumor necrosis factor agent first. Step therapy rules vary by plan and by state, so treat this as what UnitedHealthcare typically asks rather than a guarantee, and confirm the exact requirements in your own plan documents.
Documenting Medical Necessity Effectively
A prior authorization succeeds or fails on the strength of its paperwork, so the goal is a complete record the reviewer cannot send back for more information. The clinical evidence behind Skyrizi gives your gastroenterologist strong material to work with. The phase 3 ADVANCE and MOTIVATE induction trials enrolled patients who had inadequate response or intolerance to biologics or conventional therapy, and clinical remission at week 12 reached roughly 42 to 45 percent on risankizumab versus 20 to 25 percent on placebo. A well-built request usually includes three core elements.
The diagnosis and disease activity, supported by endoscopy, imaging, or biomarkers
A clear history of prior therapies tried, with drug names, dates, and the reason each was stopped
The treating gastroenterologist's statement of medical necessity
Documenting prior treatment failures precisely is what satisfies a step-therapy requirement, so vague notes like "tried other drugs" tend to trigger denials.
What to Verify in Your Own Plan
UnitedHealthcare administers many different plan designs, and the specifics of formulary placement, tier, and out-of-pocket cost differ from one to the next. Avoid assuming a particular formulary tier or copay amount applies to you, because those details live in your individual plan's documents rather than in any general policy. Check your plan's formulary, often called a prescription drug list, to confirm Skyrizi is covered and to see whether it is flagged for prior authorization or step therapy. Your benefit summary will show how the medical and pharmacy benefits split costs, which matters because the intravenous induction and subcutaneous maintenance phases may be processed differently. OptumRx and Optum Specialty Pharmacy typically handle the specialty dispensing, and calling the member services number on your insurance card lets you confirm requirements before your gastroenterologist submits.
Appealing a Denial
A denial is a common step rather than a final answer, and UnitedHealthcare provides a formal appeals process. If your request is denied, the explanation letter will state the reason, which is frequently a missing piece of documentation or an unmet step-therapy requirement rather than a judgment that Skyrizi is wrong for you. The maintenance evidence supports persistence, since the FORTIFY maintenance trial showed that continued subcutaneous risankizumab sustained clinical and endoscopic improvement through week 52 better than withdrawal. Your gastroenterologist can file an appeal that addresses the stated reason directly, adds the missing records, and includes a peer-to-peer review with the plan's medical director when appropriate. The FDA label also notes monitoring of liver enzymes during induction, and including such monitoring plans signals a complete clinical picture. Track every deadline, because appeals are time-limited.
The Bottom Line on Coverage
UnitedHealthcare does cover Skyrizi for Crohn's disease for members who meet its criteria, but the path runs through prior authorization and, in many plans, step therapy administered with OptumRx. The medication's split between intravenous induction and subcutaneous maintenance means you may encounter both a medical benefit review and a pharmacy benefit review, so anticipating two checkpoints helps. The strongest position is a request that documents a confirmed diagnosis of moderately to severely active Crohn's disease, a precise history of prior therapies, and a gastroenterologist's clear statement of medical necessity. Because plan designs differ, verify your formulary, tier, and step-therapy rules in your own UnitedHealthcare documents, and if a denial arrives, treat it as a fixable gap and use the appeal process rather than abandoning the prescription.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.